lerociclib + letrozole

The combination of lerociclib and letrozole is a treatment regimen used primarily for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This combination has shown significant efficacy in clinical trials, particularly in the LEONARDA-2 Phase 3 trial. ## Mechanism of Action Lerociclib is a highly selective oral CDK4/6 inhibitor that works by interfering with cell cycle progression, preventing cancer cells from dividing and proliferating[2][8]. It blocks the activity of cyclin-dependent kinases 4 and 6, which are enzymes that play a crucial role in cell division. Letrozole is an aromatase inhibitor that decreases the amount of estrogen in the body by blocking the enzyme aromatase, which converts androgens to estrogens[1]. Since many breast cancers are stimulated by estrogen, reducing estrogen levels can help slow or stop the growth of these tumors. ## Clinical Efficacy The LEONARDA-2 Phase 3 clinical trial evaluated lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer patients. Results showed that: - The combination significantly improved progression-free survival (PFS) compared to placebo plus letrozole (median: not reached versus 16.56 months; hazard ratio: 0.464; 95% CI: 0.293-0.733; p=0.0004)[2]. - Blinded Independent Central Review (BICR) confirmed these results (hazard ratio: 0.457; 95% CI: 0.274-0.761; p=0.0011)[2]. - For patients with measurable disease, the objective response rate was higher with lerociclib plus letrozole (62.3%) compared to the placebo group (48.5%)[2]. ## Safety Profile The safety profile of lerociclib plus letrozole shows: - Primarily hematological toxicities, with higher incidences of grade 3/4 neutropenia and leucopenia in the lerociclib group compared to placebo[2]. - Grade 3 diarrhea was infrequent (0.7% in lerociclib group)[2]. - QTc prolongation was comparable between lerociclib (4.4%, Grade 3: 1.5%) and placebo (3.5%, Grade 3: 0.7%)[2]. - No venous thromboembolism was reported[2]. - Serious adverse events were slightly higher in the lerociclib group (13.1% vs. 7.7%)[2]. - Treatment discontinuation due to adverse events was rare (0.7% with lerociclib)[2]. ## Development Status The combination is being evaluated in multiple clinical trials: - LEONARDA-2: A randomized, double-blinded, placebo-controlled Phase 3 clinical trial comparing lerociclib (150mg twice daily) with letrozole versus placebo with letrozole[3][4]. - As of September 2023, 279 patients were randomized in this trial (137 to lerociclib + letrozole, 142 to placebo + letrozole), with a median follow-up of 12.91 months[2]. This combination represents an important advancement in the treatment of HR+/HER2- breast cancer, offering a potentially effective option with a manageable safety profile.